Finance

Beta
Lists
ABUS:NASDAQ
Arbutus Biopharma Corp
$4.25
-2.30%
(-0.100) 1D
$4.25
0.00% (0.00)
After hours
Closed: Jun 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABUS...
Open
$4.34
High
$4.36
Low
$4.21
Mkt. cap
839.54M
Avg. vol.
1.80M
Volume
1.12M
P/E ratio
5.17
52-wk high
$5.10
52-wk low
$3.04
EPS
$0.82
Beta
0.63
Shares outstanding
197.54M
No. of employees
19
Open
$4.34
High
$4.36
Low
$4.21
Mkt. cap
839.54M
Avg. vol.
1.80M
Volume
1.12M
P/E ratio
5.17
52-wk high
$5.10
52-wk low
$3.04
EPS
$0.82
Beta
0.63
Shares outstanding
197.54M
No. of employees
19
News stories
From sources across the web
Profile
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
About Arbutus Biopharma Corp
CEOWilliam H. Collier
Employees19
Founded2007
HeadquartersWarminster Township, Pennsylvania, United States
SectorBiotechnology
Websitearbutusbio.com
Last report
May 13, 2026
Fiscal period
Q1 2026
EPS / Est. (CAD)
CA$1.19 / -CA$0.06
+2,270.56%beat
Revenue / Est. (CAD)
245.80M / 1.53M
+15,954.65%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CAD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
10.74M
529.00K
1.05M
179.13M
Cost of goods sold
5.50M
5.78M
5.01M
4.12M
Cost of revenue
5.50M
5.78M
5.01M
4.12M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.33M
3.04M
3.69M
5.89M
Operating expense
3.33M
3.04M
3.69M
5.89M
Total operating expenses
8.83M
8.82M
8.70M
10.01M
Operating income
1.91M
-8.29M
-7.64M
169.12M
Other non operating income
-
-
-
-
EBT including unusual items
2.52M
-7.74M
-3.76M
169.70M
EBT excluding unusual items
2.95M
-7.38M
-6.78M
169.90M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
2.52M
-7.74M
-3.76M
169.70M
Net profit margin
23.49%
-1,463.52%
-357.37%
94.73%
Earnings per share
-
-
-
-
Interest and investment income
1.04M
952.00K
877.00K
815.00K
Interest expense
-28.00K
-23.00K
-18.00K
-17.00K
Net interest expenses
1.01M
929.00K
859.00K
798.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
1.92M
-8.28M
-7.63M
169.13M
Gain or loss from assets sale
-
-
-674.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer